Compare ALZN & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALZN | BMRA |
|---|---|---|
| Founded | 2016 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.3M |
| IPO Year | 2021 | 1995 |
| Metric | ALZN | BMRA |
|---|---|---|
| Price | $1.02 | $2.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 179.6K | 17.9K |
| Earning Date | 03-11-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $0.40 |
| 52 Week High | $8.22 | $4.60 |
| Indicator | ALZN | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 25.85 | 42.26 |
| Support Level | N/A | $1.87 |
| Resistance Level | $2.59 | $2.23 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 2.96 | 16.29 |
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.